Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three intravenous anesthetic agents - ketamine, propofol, and thiopental - each with distinct pharmacological properties. Ketamine is a dissociative anesthetic that provides analgesia and amnesia while preserving muscle tone and airway reflexes. Propofol is a non-barbiturate sedative hypnotic with rapid onset and short recovery time, functioning as an antiemetic, anticonvulsant, and amnestic agent. Thiopental is a barbiturate used for induction of anesthesia, with ultrashort-acting depressant effects on the central nervous system. These agents are sometimes used in various combinations for procedural sedation and anesthesia, with the theoretical advantage of balancing their opposing cardiovascular effects and reducing individual drug doses to minimize adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + propofol + thiopental.